 PALO ALTO, Calif., Feb. 13, 2021 PRNewswire -- Kodiak Sciences Inc. Nasdaq: KOD, a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced promising 1-year durability,... 